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This study evaluated the hypothesis that the disease status of Saanen goats infected with caprine arthritis-encephalitis lentivirus (CAEV) is
associated with the focus of immune responses to viral antigens, particularly the surface envelope glycoprotein (SU). Specifically, we have
proposed that Th2 responses promote progressive immune-mediated arthritis, whereas Th1 responses restrict virus replication and
development of clinical disease. The present study determined the isotype of SU antibodies associated with progressor and long-term
nonprogressor (LTNP) status. We show that chronically infected goats that develop clinical arthritis have predominantly IgG1 antibodies to
SU during both preclinical and clinical stages of disease, whereas SU antibodies of LTNP goats are relatively biased toward IgG2. Additional
studies determined the isotype of SU antibodies induced initially by CAEV infection. These experiments show that initial IgG1-dominated
responses to SU are associated with subsequent development of preclinical inflammatory joint lesions, whereas lack of joint pathology is
associated with an IgG2 bias of initial responses to SU. Our results using the CAEV model suggest that isotype bias of SU antibodies is a
reliable indicator of clinical disease caused by lentiviruses. Isotype analysis may be a useful method to screen candidate lentiviral vaccines
intended to prevent disease progression.
D 2004 Elsevier Inc. All rights reserved.Keywords: Lentivirus; CAEV; CAEV SU; Antibody isotypesIntroduction
Caprine arthritis-encephalitis virus (CAEV) is a strictly
monocyte–macrophage tropic lentivirus that causes non-
suppurative immune-mediated arthritis in domestic goats
(Garry et al., 1995; Narayan et al., 1993). To provide insight
into the immunologic correlates that may apply to lentiviral
vaccine design, we are evaluating CAEV–host interactions
that determine the clinical course of infection.
CAEV-infected goats do not develop arthritis uniformly,
and disease status is associated with dichotomous immune
responses to viral proteins, particularly the viral surface
glycoprotein (SU). Long-term nonprogressor (LTNP) goats
that remain clinically asymptomatic have a dominant pop-
ulation of Th1 lymphocytes responsive to CAEV SU0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.03.048
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E-mail address: jdt@vetmed.wsu.edu (J.D. Trujillo).(Cheevers et al., 1997). In contrast, goats with arthritis have
enhanced activation of SU-responsive Th2 lymphocytes
(Cheevers et al., 1997) and enhanced differentiation of
plasma cells in joint lesions and regional lymph nodes
(Lechner et al., 1997; Wilkerson et al., 1995b).
Based on these observations, we have proposed that
the clinical outcome of CAEV infection is determined by
the initial focus of immune responses to viral antigens
(Cheevers et al., 1997). To address this hypothesis, the
present study evaluated the isotypes of antibodies directed
to CAEV SU in relation to disease status. We show that
preclinical and clinical phases of progressive arthritis are
associated with dominant IgG1 responses to SU, whereas
LTNP goats have relatively biased IgG2 responses to SU.
Additional experiments show that primary IgG1 responses
to SU within 20 weeks postinfection (pi) are associated
with subsequent development of joint lesions, whereas
lack of joint pathology is associated with an IgG2 bias of
initial responses to SU.
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SU antibody response and clinical disease status in CAEV
infection
The first part of this study determined CAEV SU
antibody titers utilizing sera from CAEV-infected goats with
defined parameters of clinical disease progression. The
carpal/metacarpal (C/MC) ratio, a measure of carpal joint
swelling (Cheevers et al., 1988), was used to define the
progression of clinical arthritis in seven Saanen goats orally
infected at birth with CAEV. All goats became infected as
evidenced by development of antibodies that immunopreci-
pitated all virion-associated structural proteins (Cheevers et
al., 1991). Four goats (G13, G14, G17, and G28) developed
bilateral arthritis, initially evident by C/MC ratios of >2.0 at
33 months postinfection (pi), whereas three asymptomatic
LTNP goats (G16, G18, and G24) had C/MC ratios of <2.0,
similar to four uninfected control goats (Cheevers et al.,
1991; Wilkerson et al., 1995a). At the time of necropsy (9.3
years pi), arthritic goats had C/MC ratios of 2.28–2.49,
excessive synovial fluid containing inflammatory mononu-
clear cells, radiographic changes of soft tissue mineraliza-
tion, and erosion of articular surfaces (Wilkerson et al.,
1995a). Carpal joints had inflammatory lesions consisting of
diffuse mononuclear cell infiltration with necrosis and
edema (Wilkerson et al., 1995b). In contrast, LTNP goats
had no clinically or histologically apparent arthritis (Wil-
kerson et al., 1995a, 1995b).
CAEV SU antibody titers were determined by compet-
itive inhibition ELISA (cELISA) at various times after
infection using sera from arthritic and LTNP goats. The
times selected corresponded to a preclinical phase (21–22Fig. 1. SU antibody titers of arthritic and LTNP goats. (A) Data represent SU anti
G28 developed carpal joint swelling at approximately 36 months pi. Goats G16, G
mean SU antibody titers for arthritic and LTNP goats. Error bars represent the 95%
samples and the remaining sera were designated postclinical samples.months pi), characterized by C/MC ratios of <2.0, and
several postclinical intervals for goats that developed arthri-
tis. SU antibody titers for individual goats are shown in Fig.
1A, and the relationship of antibody titers to preclinical and
postclinical phases of arthritis is shown in Fig. 1B. Results
for postclinical sera show that CAEV SU antibody titers
were approximately 20 times higher for goats with clinical
arthritis compared to LTNP goats. These data confirm
previous independent studies demonstrating a direct associ-
ation between SU antibody titers and clinical disease status
(Knowles et al., 1990; Perry et al., 1995). In addition, the
results in Fig. 1 demonstrate that SU antibody titers were
elevated approximately 10-fold during the preclinical phase
of arthritis as compared to LTNP goats.
SU antibody isotypes and clinical disease status in CAEV
infection
Previous studies have demonstrated that the disease
status of CAEV-infected goats is associated with dichoto-
mous immune responses to viral antigens. LTNP goats have
dominant Th1 responses to SU, whereas goats with arthritis
have enhanced activation of SU-responsive Th2 lympho-
cytes (Cheevers et al., 1997). As expected, dominant Th2
responses are also associated with enhanced differentiation
of plasma cells in arthritic lesions and high serum and
synovial fluid titers of polyclonal and CAEV-reactive
IgG1 antibodies (Cheevers et al., 1991; Johnson et al.,
1983; Knowles et al., 1990; Perry et al., 1995).
Based on these observations, we have proposed that the
clinical outcome of CAEV infection is determined by the
initial focus of immune responses to viral antigens
(Cheevers et al., 1997; Perry et al., 1995). To address thisbody titers for individual CAEV-infected goats. Goats G13, G14, G17, and
18, and G24 did not develop clinically apparent arthritis. (B) Data represent
confidence interval. Sera at 21 or 22 months pi were designated preclinical
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antibodies for arthritic goats G13, G14, G17, and G28 and
LTNP goats G16, G18, and G24. This approach was based
on previous studies demonstrating that activation of SU-
responsive Th1 lymphocytes is associated with an IgG2 bias
of SU antibodies reflected by relatively low IgG1/IgG2
ratios (Beyer et al., 2001; Cheevers et al., 2001). IgG1/
IgG2 ratios of SU antibodies for individual goats are shown
in Fig. 2A, and the relationship of IgG1/IgG2 ratios to
preclinical and postclinical phases of arthritis is shown in
Fig. 2B. These results demonstrate that LTNP goats had
relative low IgG1/IgG2 ratios compared to goats with
arthritis. Importantly, the results in Fig. 2 also show that
isotype ratios of SU antibodies for goats that developed
arthritis were significantly biased toward IgG1 during the
preclinical phase of infection. These results support the
hypothesis that disease progression is associated with a
Th2 focus of immune responses to CAEV infection resulting
in biased anti-SU IgG1 antibody responses.
Preclinical joint lesions following infection with CAEV
In the second part of this study, we evaluated antibody
responses to CAEV SU during the preclinical phase of
infection. In this study, disease progression was defined
by histologic examination of joint lesions, which are detect-
able before development of clinical joint swelling (Cheevers
et al., 2003). The purpose of this study was to determine if
development of joint pathology can be defined in terms of
the focus of primary immune responses to CAEV. For this
study, eight goats (G01, G02, G03, G04, G10, G12, G13,
and G14) were infected intravenously with CAEV and
monitored by measurement of C/MC ratios. Goats G01,
G02, G03, and G04 were infected with 1  106 TCID50Fig. 2. IgG1/IgG2 ratios of SU antibodies. (A) Data represent IgG1/IgG2 ratios for
for arthritic and LTNP goats. Error bars represent the 95% confidence interval.CAEV and euthanized at 99 weeks pi. Goats G10, G12,
G13, and G14 were infected with 1  104 TCID50 CAEV
and euthanized at 84 weeks pi. Serum was obtained peri-
odically for the evaluation of antibody responses to CAEV
SU. These experiments were terminated at time points
approximately corresponding to the preclinical phase of
infection defined by C/MC ratios of chronically infected
goats evaluated in Figs. 1 and 2. As expected, C/MC ratios
for goats G01, G02, G03, G04, G10, G12, G13, and G14
were in the normal range of 1.8–1.9 within the time frame
of this study (data not shown).
At necropsy, right and left carpal joints were examined
for histologic lesions. A previously described grading sys-
tem for lesion severity associated with preclinical arthritis
was utilized (Cheevers et al., 2003). Results of lesion
analyses are shown in Table 1. These data show that carpal
joints of goats G01, G03, G04, G12, and G13 had severe
inflammatory lesions predictive of the eventual develop-
ment of clinical arthritis, whereas carpal joints of goats G02,
G10, and G14 had either no lesions or mild synovial
membrane proliferative changes without infiltration of in-
flammatory cells. Based on these results, goats G01, G03,
G04, G12, and G13 were classified as progressors and goats
G02, G10, and G14 were classified as nonprogressors.
Preclinical antibody responses to CAEV SU
All goats experimentally infected with CAEV serocon-
verted for antibodies to SU by 3 weeks pi and thereafter SU
antibody responses were bimodal. Initial increases in SU
antibody titers reached a maximum by 8–12 weeks pi and
then declined. This initial response (phase I) was followed
was a second increase in antibody titers (phase II) beginning
at 20–24 weeks pi. Based on a previous study (Cheevers etindividual CAEV-infected goats. (B) Data represent mean IgG1/IgG2 ratios
Table 1
Preclinical carpal joint lesions of goats infected with CAEV
Goatsa Tissue sections with lesions or tissue sections examinedb
Cumulativec Inflammatoryd Severee
Group 1 G01 12/13 10/13 6/13
G02 5/13 0/13 0/13
G03 12/12 7/12 5/12
G04 12/13 9/12 9/12
Group 2 G10 1/10 0/10 0/10
G12 10/13 10/13 6/13
G13 12/17 12/17 7/17
G14 1/15 0/15 0/15
Pf <0.001 <0.001 <0.001
a Group 1: goats infected with 1  106 TCID50 CAEV-Co. Group 2: goats
infected with 1  104 TCID50 CAEV-Co.
b Carpal joint tissue sections were examined at 99 weeks pi (group 1) or 84
weeks pi (group 2).
c Lesion grades 1–4.
d Inflammatory lesion grades 2–4.
e Severe lesion grades 3 or 4.
f Tissue sections with lesions for goats G02, G10, and G14 were compared
to tissue sections with lesions for goats G01, G03, G04, G12, and G13
using the Mann–Whitney rank sum test.
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initial replication and immune control of the virus inoculum
(phase I) followed by establishment of persistent infection
(phase II). The developments of SU antibody responses for
goats G01, G02, G03, G04, G10, G12, G13, and G14 for
phase I and phase II are shown in Fig. 3A. Mean SU
antibody titers for nonprogressor goats G02, G10, and
G14 and progressor goats G01, G03, G04, G12, and G13
were not significantly different during phase I responses
(Fig. 3B). However, mean SU antibody titers during phase II
were >4-fold higher for progressor goats compared to non-
progressor goats (Fig. 3B).
IgG1/IgG2 ratios of SU antibodies for individual CAEV-
infected goats during phase I and phase II are shown in Fig.
4A, and the relationship of IgG1/IgG2 ratios to phase I and
phase II responses for nonprogressor and progressor goats is
shown in Fig. 4B. During phase I responses, the mean IgG1/
IgG2 ratio of SU antibodies for progressor goats G01, G03,
G04, and G13 was 4.8 times the mean IgG1/IgG2 ratio of
SU antibodies for nonprogressor goats G02, G10, and G14
(Fig. 4B). The IgG1 bias of SU antibodies for progressor
goats was also evident for sera at multiple time points
during phase II responses (Fig. 4A). During phase II, the
mean IgG1/IgG2 ratio of SU antibodies for progressor goats
G01, G03, G04, G12, and G13 was 4.2 times the mean
IgG1/IgG2 ratio for nonprogressor goats G02 and G14 (Fig.
4B). Importantly, sera drawn during phase I represent
primary antibody responses to the virus inoculum. There-
fore, we conclude that the disease status of CAEV-infected
goats is predicted by the focus of initial antibody responses
to viral SU. Specifically, initial IgG1-biased responses
predict the development of joint lesions and eventual
development of clinical arthritis, whereas the LTNP status
is predicted by the initial IgG2-biased responses.Discussion
This study shows that CAEV-infected goats with clinical
arthritis or inflammatory joint lesions have dominant IgG1
antibody responses to viral SU. In contrast, persistently
infected LTNP goats that remain clinically asymptomatic
have relatively biased IgG2 responses to SU. Importantly,
chronically infected goats that developed arthritis had IgG1
antibody responses during the preclinical phase of infection,
and goats that developed preclinical inflammatory joint
lesions had initial IgG1 responses to the virus inoculum.
These results extend previous studies demonstrating that
LTNP goats have a dominant population of SU-responsive
Th1 lymphocytes, whereas goats with arthritis have en-
hanced activation of Th2 lymphocytes (Cheevers et al.,
1997; Perry et al., 1995).
The principal conclusion of this study is that the disease
status of CAEV-infected goats is predicted by the focus of
primary immune responses to viral SU. These results,
together with previous studies (Cheevers et al., 1997; Perry
et al., 1995), indicate that disease progression is dependent
on dominant Th2 immune responses to CAEV, whereas Th1
immune responses prevent disease progression. The depen-
dence of disease progression on Th2 immune responses is
supported by independent studies demonstrating that ap-
proximately 70% of inflammatory infiltrates in joint lesions
are IgG1+ plasma cells (Lechner et al., 1997; Wilkerson et
al., 1995b). Non-neutralizing anti-SU IgG1s in vivo are
hypothesized to bind virus and form antibody–virus com-
plexes that can enter macrophages by phagocytosis of the Fc
receptor or complement mediated endocytosis resulting in
enhanced infection of macrophages and increased virus
replication. Entry of antibody–virus complexes can also
result in macrophage activation and the production of
inflammatory cytokines like interleukin 1 (IL 1), IL-6 IL
8, and tumor necrosis factor alpha (TNF a) that contribute to
T and B cell activation, an influx of inflammatory cells to
the synovium resulting in the production of inflammatory
mediators like RANTES (regulated upon activation, normal
T expressed and secreted), M1P-1h (macrophage inflamma-
tory protein-1 beta), MCP-1 (monocyte chemotactic protein-
1), and complement (Gangopadhyay and Jolly, 2003),
degradation of soft tissue components and exuberant pro-
duction of anti-SU immunoglobulin. This hypothesis is
supported by the observation that goats with extant IgG1
memory induced by immunization with SU develop arthritis
following challenge infection (Cheevers et al., 1994; K.R.
Snekvik and W.P. Cheevers, unpublished). In contrast,
vaccination with plasmid DNA expressing the CAEV env
gene induces Th1 responses to SU that suppress virus
replication and development of arthritis following challenge
(Cheevers et al., 2003). Thus, isotype analysis may be a
useful method to screen candidate lentiviral vaccines
intended to restrict viral replication and prevent disease.
Numerous studies of HIV infection have also correlated
low virus loads and LTNP status with dominant Th1
Fig. 3. Preclinical SU antibody responses following CAEV infection. Sera at 1, 2, 3, 4, 8, 12, 16, and 20 weeks pi were designated phase I samples and the
remaining sera drawn at monthly intervals were designated phase II samples. (A) Data represent mean SU antibody titers for individual CAEV-infected goats
for phase I and phase II. Goats G01, G03, G04, G12, and G13 had inflammatory joint lesions at necropsy (progressor goats), whereas G02, G10, and G14
(nonprogressor goats) did not have inflammatory joint lesions (Table 1). (B) Data represent mean SU antibody titers for progressor goats and nonprogressor
goats. Error bars represent the 95% confidence interval.
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1996; Ngo-Giang-Huong et al., 2001). Several studies have
suggested that HIV disease progression involves a shift
from Th1 to Th2 responses (Clerici and Shearer, 1993;
Klein et al., 1997). However, the concept of a shift in the
focus of immune responses as a component of AIDS
pathogenesis is controversial (Fakoya et al., 1997; Graziosi
et al., 1994). The apparent change in cytokine balance
associated with AIDS progression may reflect Th1 depletion
(Meyaard et al., 1996), which could be due to apoptosis
mediated by type 2 cytokines (Clerici and Shearer, 1994). In
our longitudinal study, anti-SU antibody isotypes early in
lentivirus infection predicted disease outcome and an anti-
body isotype shift was not apparent. Moreover, CAEV-
infected goats with an established LTNP status after about
3 years pi do not progress to clinical arthritis (Cheevers et
al., 1988; Wilkerson et al., 1995a,1995b). Thus, we suggest
that the clinical course of CAEV infection is determined by
the relative dominance of Th lymphocyte phenotypes acti-
vated at the time of initial virus exposure. In this context, it
is well established that the course of certain other infectious
diseases, such as murine leishmaniasis, is determined by
differential priming of Th subsets (Reiner and Locksley,
1995).
Understanding of the mechanisms of specific Th subset
priming is incomplete. However, several factors that influ-
ence Th lymphocyte priming have been identified, including
immunogenetics (Chaturvedi et al., 1996; Murray et al.,
1989, 1992; Pearson et al., 1997), antigen characteristics
and antigen dose (Chaturvedi et al., 1996; Chirmule et al.,
1992, 1994; Pfeiffer et al., 1991; Power et al., 1998), and
modulating proteins (Stumptner-Cuvelette et al., 2001).Collective results from this and other small ruminant lenti-
virus studies suggest that disease progression in CAEV
infection is more strongly influenced by host rather than
viral factors. The importance of immunogenetic factors,
suggested by the antibody response data presented here,
was also addressed previously in studies using monozygotic
twin lambs inoculated with phenotypically distinct strains of
ovine lentiviruses (OvLV). In these studies, the severity of
lymphoid interstitial pneumonia was host determined and
unrelated to the in vitro phenotype of OvLV (de la Concha-
Bermejillo et al., 1995). In a subsequent study, Woodward et
al. (1995) determined the phenotype of OvLV isolated from
alveolar macrophages of these lambs and confirmed the
independence of OvLV phenotype and lung lesion severity.
In summary, we show that the disease progression in
CAEV infection is associated specifically with a dominant
IgG1 antibody response to viral SU detected before devel-
opment of immune-mediated arthritis. We suggest that the
clinical outcome of infection by strictly macrophage tropic
ruminant lentiviruses is determined primarily by immuno-
genetic criteria that govern activation of distinct arms of the
immune system.Materials and methods
CAEV-infected goats
The first part of this study utilized serum from seven
CAEV-infected Saanen goats. These goats were orally
infected at birth with the 79-63 isolate of CAEV (Crawford
et al., 1980). Four goats (G13, G14, G17, and G28)
Fig. 4. IgG1/IgG2 ratios of preclinical SU antibodies. (A) Data represent anti-SU IgG1/IgG2 ratios for individual CAEV-infected goats at various time points
corresponding to phase I and phase II. Sera from 1 to 20 weeks pi were designated phase I samples and the remaining sera were designated phase II samples.
(B) Data represent mean IgG1/IgG2 ratios for progressor goats and nonprogressor goats for phase I and phase II sera. Error bars represent the 95% confidence
interval.
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initially evident at approximately 33 months pi, and three
goats (G16, G18, and G24) remained clinically asymptom-
atic (Cheevers et al., 1991; Wilkerson et al., 1995a, 1995b).
The second part of this study utilized two groups of four
yearling goats obtained from a CAEV-free Saanen breeding
herd that were inoculated with the Co isolate of CAEV
(Narayan et al., 1980). The virus inoculum was derived by
transfection of goat synovial membrane (GSM) cells with an
infectious molecular clone of CAEV-Co proviral DNA
(Pyper et al., 1986; Saltarelli et al., 1990). Virus infectivity
titers were determined by formation of syncytia in GSM
cells and expressed as 50% tissue culture infectious dose
(TCID50) as described (Klevjier-Anderson and Cheevers,
1981). Four goats in group 1 (G01, G02, G03, and G04)
were inoculated intravenously with 1  106 TCID50 of
CAEV-Co. Four goats in group 2 (G10, G12, G13, and
G14) were inoculated intravenously with 1  104 TCID50 of
CAEV-Co.
CAEV SU antibody titers
Competitive inhibition ELISA (cELISA) (VMRD, Pull-
man, WA) was utilized to monitor the development of
CAEV SU-specific antibodies as described (O¨zyo¨ru¨k et
al., 2001). Briefly, soluble SU from the medium of
CAEV-63-infected GSM cells was captured on 96-well
microtiter plates using anti-SU monoclonal antibody
(mAb) F7-299. Reactivity of goat sera with captured SU
was determined by inhibition of SU binding by a second
horseradish peroxidase (HRP)-conjugated anti-SU mAb
(GPB-74A). SU antibody titers were calculated by end pointcELISA reactivity using serial dilutions of goat sera. End
point titers were extrapolated by linear regression analysis
and defined by background inhibition of mAb GPB-74A
binding by control sera.
Anti-SU IgG1 and IgG2
IgG1/IgG2 ratios of SU antibodies were determined by
Western blot of anti-bovine IgG1 and IgG2 mAb (Serotec,
Oxford, UK) against serial dilutions of goat sera bound to
SU. Details of this method were described previously
(Beyer et al., 2001). Briefly, mAb F7-299 affinity purified
SUs transferred to nitrocellulose membranes from SDS-
PAGE gels were reacted with serial dilutions of goat sera.
Paired blots were then reacted with anti-IgG1 or IgG2 mAb
and developed with ECL reagent following incubation with
HRP-conjugated donkey anti-mouse IgG. Blots were ana-
lyzed by densitometry using an IS1000 Digital Imaging
System (Alpha Innotec, San Leandro, CA). Endpoints were
extrapolated by linear regression analysis of ECL signal
intensity plotted against serum dilutions. To calculate IgG1/
IgG2 ratios, linear regression plots were corrected for the
relative binding affinities of the anti-IgG1 and anti-IgG2
mAb at dilutions utilized in the Western blots.
Histopathology
The two groups of goats infected with CAEV-Co were
euthanized at 99 and 84 weeks pi, and carpal joint arthritis
was evaluated at necropsy. Samples of carpal joint syno-
vium were fixed in 10% buffered formalin and embedded in
paraffin blocks. Paraffin-embedded tissues were sectioned at
J.D. Trujillo et al. / Virology 325 (2004) 129–136 1355 Am and stained with hematoxylin and eosin for light
microscopy. Carpal joint tissue sections were evaluated for
the presence and severity of arthritis using a histologic
grading system as described (Cheevers et al., 2003). Briefly,
grade 1 lesions have mild synovial membrane hyperplasia
with no perivascular infiltration of inflammatory cells.
Grade 2 lesions have more advanced synovial membrane
hyperplasia and foci of perivascular inflammation in the
subsynovial connective tissue. Severe grade 3 lesions have
extensive synovial membrane hyperplasia with villous hy-
pertrophy and diffuse infiltration of inflammatory cells. The
most severe lesions (grade 4) are degenerative, with mark-
edly edematous synovial villi and villous and periarticular
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